Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...
Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Stream NBC 5 for free, ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Shares of Merck slid Tuesday after the ...
As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...
Robert F. Kennedy Jr. and a group of personal injury lawyers have long accused Merck & Co. of “disease mongering” to boost ...
Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date. The company said the ...
FILE - A Merck scientist conducts research on Feb. 28, 2013, in West Point, Pa. (AP Photo/Matt Rourke, File) (Matt Rourke, Copyright 2017 The Associated Press. All ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results